Stay Ahead. Stay Informed. Know More. In Less. Kolkata's #1 news channel, trusted across India for fast, credible news from India and around the world.

Dose of Affordability: Govt Makes 35 Essential Medicines Easier on the Pocket

Swarnadwip Nath Published Aug 03, 2025, 06:09 PM Updated Sep 18, 2026, 12:30 PM

The Indian government has delivered major relief to patients and families across the nation by reducing the prices of 35 essential medicines. Announced on August 3, 2025, this decision by the National Pharmaceutical Pricing Authority (NPPA), under the Ministry of Chemicals and Fertilisers, is expected to make vital drugs significantly more affordable and improve healthcare access, especially for those managing chronic or life-threatening illnesses.

A Move to Lighten the Burden

India’s pharmaceutical market is among the world’s largest, but for millions living with chronic conditions—like diabetes, heart disease, infections, and psychiatric disorders—the cost of long-term medication can be daunting. The new price control order, as notified by the NPPA, directly addresses this by setting retail price ceilings on select formulations widely used in Indian homes and hospitals.

The price reduction covers a broad spectrum of categories:

Anti-inflammatory drugs (for pain and swelling)
Cardiovascular medicines (for heart and blood pressure issues)
Antibiotics (for infections)
Anti-diabetic agents
Psychiatric medicines
Pediatric suspensions and nutritionals

Why Was This Needed?

Healthcare activists and patient advocates have long called for government action on medicine prices, which remain one of the largest out-of-pocket expenses for Indian households. With chronic diseases on the rise, and inflation affecting everything from hospital bills to basic drugs, this move aims to curb profiteering, ensure fairness, and guarantee access to quality healthcare for all segments of society.

What’s Changed: Key Drug Price Highlights

Among the most notable medicines and their newly fixed retail prices are:

Aceclofenac + Paracetamol + Trypsin Chymotrypsin (pain/inflammation):

Dr Reddy’s: ₹13 per tablet
Cadila Pharmaceuticals: ₹15.01 per tablet

Atorvastatin 40 mg + Clopidogrel 75 mg (heart health):

₹25.61 per tablet

Cefixime + Paracetamol (children’s antibiotic + fever):

Included in oral suspension forms

Cholecalciferol (Vitamin D drops)

Covered for supplementation needs

Diclofenac Injection:

₹31.77 per ml (crucial for pain, arthritis, surgical recovery)

Newer anti-diabetics (Empagliflozin, Sitagliptin, Metformin):

Included to address the growing diabetes burden

The NPPA clarified that these prices are exclusive of Goods and Services Tax (GST), which may be added where applicable. All previous price orders on these medicines and their manufacturers now stand superseded.

How Will This Affect Patients?

Patients with long-term conditions are expected to save hundreds or even thousands of rupees annually, particularly those requiring daily or combination therapies. For instance, cardiovascular patients and diabetics—two of the largest chronic patient groups in India—are immediate beneficiaries.

Pediatric medicines and vital injections being included signal that the government also focused on child health and critical care affordability.

Retailers and pharmacists are now required to display updated price lists prominently. Non-compliance may lead to stiff penalties, including the repayment of any overcharged amount plus interest, under the Drugs (Prices Control) Order (DPCO), 2013, and the Essential Commodities Act, 1955.

The Broader Picture: Ensuring Compliance & Reach

Manufacturers are mandated to update their price lists via the Integrated Pharmaceutical Database Management System (IPDMS) and share them with both the NPPA and state drug controllers. Consumers are strongly encouraged to double-check price displays at chemists and verify their bills, ensuring they aren’t overcharged.

This step is yet another in a series of government actions aimed at making healthcare more accessible, building on schemes like Ayushman Bharat and the expansion of Jan Aushadhi Kendras that offer generic medicines at discounted prices.

Industry and Public Response

Health experts, patient groups, and many within the pharmaceutical sector have praised the move as a long-awaited step toward equity, though some manufacturers have urged for a balanced approach, ensuring costs do not impact quality or supply.

A senior NPPA official summarized the change: “Our aim is simple—make sure no Indian is denied affordable treatment solely because of high medicine prices. Today, we’ve taken another step in that direction.”

Relevant Sources Mathrubhumi, Midday, National Herald India, Greater Kashmir, Madhyamam, IANS Live

Stay Ahead – Explore Now! No news available